Exelixis
EXEL
#2109
Rank
NZ$12.18 B
Marketcap
$42.70
Share price
-1.53%
Change (1 day)
17.39%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Cash on Hand

Cash on Hand as of June 2024 : NZ$1.61 B

According to Exelixis's latest financial reports the company has NZ$1.61 B in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Exelixis - Cash on Hand chart (from 2000 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31NZ$1.57 B-23.63%
2022-12-31NZ$2.06 B-3.8%
2021-12-31NZ$2.14 B27.69%
2020-12-31NZ$1.67 B32.79%
2019-12-31NZ$1.26 B22.28%
2018-12-31NZ$1.03 B89.22%
2017-12-31NZ$0.54 B-9.91%
2016-12-31NZ$0.60 B148.01%
2015-12-31NZ$0.24 B32.86%
2014-12-31NZ$0.18 B-37.7%
2013-12-31NZ$0.29 B-41.18%
2012-12-31NZ$0.50 B101.62%
2011-12-31NZ$0.24 B17.58%
2010-12-31NZ$0.21 B-24.84%
2009-12-31NZ$0.28 B-38.07%
2008-12-31NZ$0.45 B29.43%
2007-12-31NZ$0.35 B38.4%
2006-12-31NZ$0.25 B16.76%
2005-12-31NZ$0.21 B-0.01%
2004-12-31NZ$0.21 B-40.37%
2003-12-31NZ$0.36 B-14.01%
2002-12-31NZ$0.42 B-22.65%
2001-12-31NZ$0.54 B115.9%
2000-12-31NZ$0.25 B1823.63%
1999-12-31NZ$13.2 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
NZ$6.10 B 276.67%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$11.77 B 626.96%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$18.35 B 1,033.13%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$10.75 B 563.97%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$15.03 B 828.24%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$41.17 B 2,442.42%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$11.47 B 608.68%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$45.84 M-97.17%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.12 B-92.28%๐Ÿ‡บ๐Ÿ‡ธ USA